Ascendiant Capital Markets Issues Positive Forecast for Daxor (NASDAQ:DXR) Stock Price

Daxor (NASDAQ:DXR) had its price objective hoisted by analysts at Ascendiant Capital Markets from $24.75 to $25.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would indicate a potential upside of 210.56% from the stock’s previous close.

Daxor Stock Performance

DXR stock opened at $8.05 on Monday. Daxor has a 1-year low of $6.55 and a 1-year high of $10.00. The business has a 50 day simple moving average of $7.79 and a two-hundred day simple moving average of $8.48.

Insiders Place Their Bets

In other Daxor news, CEO Michael Richard Feldschuh purchased 3,360 shares of the company’s stock in a transaction on Monday, March 10th. The stock was acquired at an average cost of $7.68 per share, for a total transaction of $25,804.80. Following the purchase, the chief executive officer now directly owns 210,852 shares of the company’s stock, valued at $1,619,343.36. This trade represents a 1.62 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 59.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC grew its position in shares of Daxor Co. (NASDAQ:DXR) by 87.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 27,821 shares of the company’s stock after acquiring an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 at the end of the most recent reporting period. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.